Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of...
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions
- Conditions
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Palo Alto Medical Foundation
- Target Recruit Count
- 36
- Registration Number
- NCT00500045
- Locations
- 🇺🇸
Palo Alto Medical Foundation Department of Ophthalmology, Palo Alto, California, United States
To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Palo Alto Medical Foundation
- Target Recruit Count
- 63
- Registration Number
- NCT00493064
- Locations
- 🇺🇸
Palo Alto Medical Foundation Department of Ophthalmology, Palo Alto, California, United States
Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)
- Conditions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2007-02-05
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 80
- Registration Number
- NCT00431145
- Locations
- 🇩🇪
University of Munich, Munich, Germany
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
- Conditions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1300
- Registration Number
- NCT00378833
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2006-03-21
- Lead Sponsor
- Foundation Research, Florida
- Target Recruit Count
- 30
- Registration Number
- NCT00304993
- Locations
- 🇺🇸
Foundation Research, St. Petersburg, Florida, United States
Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)
- Conditions
- Interventions
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 48
- Registration Number
- NCT00298909
- Locations
- 🇩🇪
University of Leipzig Heart Center, Leipzig, Germany
Obesity and Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT00262964
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 221
- Registration Number
- NCT00246376
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
The Low HDL On Six Weeks Statin Therapy (LOW) Study
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Craigavon Area Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00238004
- Locations
- 🇬🇧
Craigavon Cardiac Centre, Craigavon, United Kingdom
Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-01-29
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70
- Registration Number
- NCT00232531
- Locations
- 🇬🇧
Oxford University, Oxford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.